A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Peter Martin(Northwestern University), John P. Leonard(New York University), LeAnn Ridling(Washington University in St. Louis), Kami J. Maddocks(The Ohio State University), Jia Ruan(Cornell University), Kristie A. Blum(Emory University), Steven Park(Levine Cancer Institute), Christopher Dittus(Palmetto Hematology Oncology), Nancy L. Bartlett(Washington University in St. Louis), Xiangao Huang(Cornell University), Zhengming Chen(Cornell University), Selina Chen‐Kiang(NewYork–Presbyterian Hospital), Maurizio DiLiberto(NewYork–Presbyterian Hospital), Giorgio Inghirami(Cornell University)
Cited by 84
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k